20,000 Shares in Accuray Incorporated (NASDAQ:ARAY) Purchased by Caprock Group LLC

Caprock Group LLC purchased a new stake in shares of Accuray Incorporated (NASDAQ:ARAY) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 20,000 shares of the medical equipment provider’s stock, valued at approximately $36,000.

Several other hedge funds have also added to or reduced their stakes in ARAY. The Manufacturers Life Insurance Company lifted its stake in Accuray by 13.3% in the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 5,273 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Accuray by 9.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 6,583 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Accuray by 0.3% in the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock worth $5,118,000 after buying an additional 7,500 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Accuray by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock valued at $509,000 after purchasing an additional 8,864 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 15,209 shares in the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Price Performance

ARAY opened at $2.03 on Tuesday. The stock has a 50-day moving average price of $1.84 and a 200-day moving average price of $1.83. The firm has a market cap of $204.15 million, a PE ratio of -11.76 and a beta of 1.40. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $3.05. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The company had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. Sell-side analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.